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http://dx.doi.org/10.1016/j.ccell.2015.04.010SUMMARYThe BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a promising anticancer
target. We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high
affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its anti-
apoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses
growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity
at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial
patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo.
Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome.INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality
in the United States, accounting for more deaths than breast,
prostate, and pancreatic cancers combined (Jemal et al.,
2007). Upregulation of antiapoptotic Bcl2 family members (i.e.,
Bcl2, Bcl-XL, and Mcl-1) and dysregulation of proapoptotic fam-
ily members (i.e., Bad, Bim, Bax, Bak, etc.) are involved in the
mediation of chemo- or radioresistance in human lung cancers
(Sartorius and Krammer, 2002; Song et al., 2005), suggesting
that Bcl2 family members have the potential to be critical targets
for lung cancer treatment.
The Bcl2 family members have homology clustered within four
conserved Bcl2 homology (BH) domains: BH1, BH2, BH3, and
BH4 (Kelekar and Thompson, 1998). The BH1, BH2, and BH3
domains form the surface binding pocket of Bcl2 that mediatesSignificance
Here, we report a smallmolecule, BDA-366, that selectively targ
molecule to a cell death inducer through a conformational cha
version by BDA-366 and illuminate a direction for the developm
by RAD001 upregulates Bcl2 in vitro and in vivo. Accordingly,
with BDA-366 and RAD001 was observed in vitro and in vivo.
a more effective strategy against lung cancer.
852 Cancer Cell 27, 852–863, June 8, 2015 ª2015 Elsevier Inc.protein-protein interactions between Bcl2 family members (Cas-
telli et al., 2004; Wang et al., 2000). This hydrophobic surface
binding pocket is required for the antiapoptotic function of
Bcl2, as studies have shown that mutations at this site abolish
the biological function of Bcl2 (Yin et al., 1994). BH3-mimetic
Bcl2 inhibitors ABT-737 and ABT-263 (the oral form of ABT-
737) bind to the hydrophobic pocket of Bcl2 or Bcl-XL with a
high affinity and subsequently disrupt the antiapoptotic function
of Bcl2 and Bcl-XL with potent antitumor effect (Konopleva et al.,
2006; Oltersdorf et al., 2005; Tse et al., 2008). However, ABT-737
and ABT-263 can induce thrombocytopenia due to their inhibi-
tory effects on both Bcl2 and Bcl-XL (Schoenwaelder et al.,
2011). To generate a Bcl2-selective inhibitor, a tethered indole
was incorporated into ABT-263 to fill the P4 hotspot, which
specifically interacts with Asp103 of Bcl2, but not Glu96 of
Bcl-XL, leading to the generation of the Bcl2-selective inhibitorets theBH4 domain of Bcl2 and converts Bcl2 froma survival
nge. Our results provide mechanistic insights into Bcl2 con-
ent of BH4-based anticancer agents. The inhibition of mTOR
a synergistic antitumor effect through combined treatment
This study has significant translational value and may foster
Figure 1. BDA-366 Targets the BH4Domain
of Bcl2 and Potently Suppresses Lung
Cancer Cell Growth
(A) Structural modeling of BDA-366 in the BH4
domain binding pocket of Bcl2 protein.
(B) Expression of Bcl2 was analyzed by western
blot in normal SAECs and SCLC and NSCLC cell
lines.
(C and D) A panel of NSCLC (C) and SCLC (D) cell
lines and SAECs were treated with BDA-366
(1 mM) for 72 hr. Cell viability was determined by
analyzing Annexin-V/PI binding by FACS. Error
bars represent ± SD.
See also Figure S1 and Tables S1 and S2.ABT-199 (Souers et al., 2013). Since ABT-199 did not cause
thrombocytopenia in vivo (Souers et al., 2013), this suggests
that highly selective inhibition of Bcl2 may benefit the develop-
ment of improved Bcl2 antagonists.
The BH4 region is a survival domain that is required for the
antiapoptotic function of Bcl2 as demonstrated by the complete
abolition of the antiapoptotic activity of Bcl2 or conversion of
Bcl2 from a survival protein into a proapoptotic molecule when
the BH4 domain is removed (Cheng et al., 1997; de Moissac
et al., 1999; Hirotani et al., 1999; Hunter et al., 1996; Reed
et al., 1996), indicating that the BH4 is an ideal target for
screening of small molecules that may convert Bcl2 into a death
molecule in tumor tissues for anticancer therapeutics. The major
goal of the present study is to identify a small-molecule Bcl2 BH4
domain antagonist for lung cancer therapy.
RESULTS
Screening of Small Molecules Targeting the BH4
Domain of Bcl2
A library containing 300,000 small molecules from the Na-
tional Cancer Institute (NCI) was used to dock the structural
pocket of the BH4 domain (amino acids [aa] 6–31; PDB ID codes:
1G5M and 1G5O) using the University of California, San
Francisco (UCSF) DOCK 6.1 program suite (Figure 1A, left) as
we previously described (Park et al., 2013). The small moleculesCancer Cell 27, 852–were ranked according to their energy
scores. The top 200 small molecules
were selected for screening of cytotox-
icity in human lung cancer cells by
sulforhodamine B (SRB) assay as previ-
ously described (Liu et al., 2012; Vichai
and Kirtikara, 2006). Among these small
molecules, the compound NSC639366
(C24H29N3O4, molecular weight [MW]
423.50) had the most potent activity
against human lung cancer cells. We
named this lead compound small-mole-
cule Bcl2 BH4 domain antagonist, or
BDA-366. The molecular modeling of
this lead in complex with the Bcl2 BH4
domain is shown in Figure 1A (right).
The effect of BDA-366 on cell growth
and apoptosis was measured by SRBassay and Annexin-V/propidium iodide (PI) binding, respectively,
in both small cell lung cancer (SCLC) and non-small-cell lung
cancer (NSCLC) cell lines that express various levels of endoge-
nous Bcl2. Results indicate that NSCLC cell lines (i.e., H157,
Calu-1, H358, H460, and H1975) and SCLC cell lines (i.e.,
DMS53, DMS153, H146, and H69) that express relatively higher
levels of Bcl2 were more sensitive to BDA-366. In contrast, lung
cancer cell lines expressing relatively lower or undetectable
levels of endogenous Bcl2 (i.e., NSCLC cell lines A549 and
H1299; SCLC cell lines DMS114 and H128) were less sensitive
to BDA-366 (Figures 1B and 1C; Tables S1 and S2). It seems
that expression levels of Mcl-1 or Bcl-XL did not significantly
affect sensitivity of cells to BDA-366. Based on our findings,
we propose that the apoptotic response of BDA-366 may be
dependent on the expression levels of Bcl2 in lung cancer cell
lines. Importantly, BDA-366 showed less sensitivity to normal
small airway epithelial cell line (SAEC) (Figure 1C), indicating a
relative selectivity against cancer cells compared to normal cells.
BDA-366 Selectively Binds to Bcl2 at the BH4 Domain
and Induces Cell Killing
Purified recombinant wild-type (WT) and a panel of Bcl2 BH
domain deletion mutant proteins (i.e., DBH1, DBH2, DBH3, and
DBH4) were commercially obtained from ProteinX Lab as previ-
ously described (Wang et al., 2008; Xie et al., 2014). To directly
measureBDA-366/Bcl2binding,afluorescencepolarizationassay863, June 8, 2015 ª2015 Elsevier Inc. 853
with a fluorescent Bak peptide (50-FAM-GQVGRQLAIIGDDINR)
was performed as previously described (Bruncko et al., 2007;
Enyedy et al., 2001; Wang et al., 2000; Zhang et al., 2002).
We found that BDA-366 directly binds to Bcl2 with high binding
affinity (Ki = 3.3 ± 0.73 nM) (Figure S1A). Deletion of BH1,
BH2, or BH3 from Bcl2 protein did not significantly affect its
BDA-366 binding. However, the BH4 domain-deficient Bcl2
mutant protein (DBH4) failed to bind BDA-366 (Figure S1A).
These findings indicate that BDA-366 selectively binds to Bcl2
via the BH4 domain. Importantly, BDA-366 did not bind to other
Bcl2 family members, including Bcl-XL, Mcl-1, or Bfl-1/A1 (Fig-
ure S1B), indicating the specificity of its Bcl2 binding.
Structural modeling analysis by computational program re-
veals that BDA-366 is associated with eight amino acids (i.e.,
Asp10, Asn11, Arg12, Glu13, Met16, Lys17, His20, and Asp31)
in the BH4 domain. We generated a panel of Bcl2 mutants within
the BH4 domain at the specific residues that were identified by
the initial docking simulations, including D10A, N11A, R12A,
E13A, M16A, K17A, H20A and D31A Bcl2 mutants. We also
created a compound Bcl2 mutant D10A/N11A/R12A/E13A
(AAAA). First, the recombinant proteins of these mutants were
generated for BDA-366/Bcl2 binding analysis using a competi-
tive fluorescence polarization as described in Supplemental
Experimental Procedures. Ki values were as follows: D10A/
4.8 ± 0.41 nM, N11A/4.1 ± 0.67 nM, R12A/4.3 ± 0.54 nM,
E13A/4.5 ± 0.71 nM, M16A/3.9 ± 0.31 nM, K17A/4.2 ±
0.45 nM, H20A/3.8 ± 0.47 nM, D31A/3.7 ± 0.91 nM, and
AAAA/598.64 ± 0.12 nM. These findings indicate that single
mutation at each individual residue did not significantly reduce
Bcl2’s ability to bind BDA-366, but the AAAABcl2mutant protein
had remarkably decreased BDA-366 binding. Second, WT and
all Bcl2mutants were exogenously overexpressed in H1299 cells
that express undetectable levels of endogenous Bcl2. Results
indicate that overexpression of exogenous WT or each of the
Bcl2 mutants in H1299 cells potently inhibited cisplatin-induced
apoptotic cell death (Figures S1C and S1D), indicating that these
Bcl2 mutants retain standard antiapoptotic function. However,
overexpression of exogenous WT and each of the Bcl2 single-
site mutants in H1299 cells failed to prolong cell survival when
cells were exposed to BDA-366 and exhibited enhanced sensi-
tivity to BDA-366 (Figure S1E), indicating that BDA-366 not
only overcomes Bcl2’s antiapoptotic function but also may
convert these Bcl2 proteins into death molecules. In contrast,
overexpression of the compound Bcl2 AAAAmutant significantly
prolonged cell survival when cells were exposed to BDA-366
(Figure S1E), suggesting that compound mutations (AAAA) at
BDA-366 binding residues lead to a phenotype that is resistant
to BDA-366. This suggests that BDA-366 binding to these four
amino acids (D10, N11, R12, and E13) in the BH4 domain is crit-
ical for BDA-366 regulation of Bcl2 and induction of apoptosis.
To determine whether Bcl-2 is the relevant target at the cellular
level and whether cell killing is truly dependent on this particular
mechanism, Bcl2 was specifically knocked down using three
different Bcl2 small hairpin RNAs (shRNAs) that target different
regions in the Bcl2 gene in five lung cancer cell lines, including
two NSCLC cell lines (H460 and H157) and three SCLC cell lines
(DMS53, DMS153, and H146). Stable expression of Bcl2
shRNA1, shRNA2, or shRNA3 efficiently depleted the endoge-
nous Bcl2 in both NSCLC and SCLC cell lines (Figure S1F).854 Cancer Cell 27, 852–863, June 8, 2015 ª2015 Elsevier Inc.This effect of shRNA on Bcl2 expression was highly specific
because the control shRNA had no effect. Cells expressing
Bcl2 shRNA1, shRNA2, shRNA3, or control shRNA were treated
with BDA-366 (1 mM) for 72 hr. The level of apoptotic cell death
was determined by analysis of Annexin-V/PI binding by fluores-
cence-activated cell sorting (FACS) as we previously described
(Deng et al., 2001, 2006). Importantly, depletion of endogenous
Bcl2 from these lung cancer cell lines by Bcl2 shRNA1, shRNA2,
or shRNA3 resulted in significantly reduced sensitivity of cells to
BDA-366 (Figure S1G).
We further examined whether expression of exogenous Bcl2
can restore the sensitivity of Bcl2-silenced lung cancer cells
to BDA-366, and whether the BDA-366/BH4 binding is essential
for such effect. WT and BDA-366 binding-deficient D10A/N11A/
R12A/E13A (AAAA) Bcl2 mutant cDNA in pCIneo or vector-only
control were transfected into H460 or DMS53 cells expressing
Bcl2 shRNA1. It has been reported that if the shRNA is directed
to the 30 UTR or 50 UTR of the gene, the effect of the shRNA can
be rescued by ectopically expressing the protein using theWT or
mutant cDNA (Lassus et al., 2002; Lim et al., 2009). Because
Bcl2 shRNA1 targets the 50 UTR of endogenous Bcl2, the
silencing effect of shRNA1 on Bcl2 expression could be rescued
by transfection of exogenous WT or AAAA Bcl2 mutant, as
shown in Figure S1H. After transfection, cells were treated with
BDA-366 or the BH3 mimetic ABT-199 at the indicated concen-
trations for 72 hr. Results reveal that expression of exogenous
WT Bcl2 restored sensitivity of cells to both BDA-366 and
ABT-199 (Figures S1I and S1J), indicating that both BDA-366
and ABT-199 are selective Bcl2 inhibitors. However, expression
of AAAA only restored the sensitivity of cells to ABT-199, but not
to BDA-366 (Figures S1I and S1J), indicating that compound
mutations in the BH4 domain result in a selective resistance to
BDA-366 while maintaining sensitivity to the BH3 mimetic
(ABT-199). These data suggest that BDA-366, but not ABT-
199, acts as a unique BH4 domain inhibitor. The apoptotic effect
of BDA-366 on lung cancer cells requires its BH4 binding.
To test whether BDA-366 reacts with DNA as a crosslinker,
electrophoretic mobility shift assay (EMSA) was performed as
previously described (Bartel et al., 2012). Cisplatin, a known
DNA binding agent, was used as positive control. Plasmid
pUC19 DNA was incubated with BDA-366 or cisplatin. Intrigu-
ingly, cisplatin, but not BDA-366, can bind to pUC19 DNA to
cause mobility shift (Figure S1K). This helps to rule out the pos-
sibility of BDA-366 as DNA binding agent.
BDA-366 Induces Bcl2 Conformational Change and
Abrogates Bcl2 Survival Function
A prior report indicates that the interaction between the nuclear
orphan receptor Nur77/TR3 and Bcl2 or the binding of p53 to
Bcl2 causes a conformational change in Bcl2 that induces the
‘‘exposure’’ of its own BH3 domain, leading to loss of Bcl2’s
antiapoptotic activity (Deng et al., 2006; Lin et al., 2004). Further-
more, removal of theBH4domain fromBcl2 by caspase-3 results
in a conversion of Bcl-2 froma survival protein to aBax-like death
molecule (Cheng et al., 1997). Since BDA-366 is a BH4 domain
binding molecule, its binding to BH4 may result in a similar
conformational change in Bcl2 to alter its function. It has been re-
ported that the Bcl2/BH3 domain-specific antibody can detect
conformational change in the BH3 domain of Bcl2 (Deng et al.,
Figure 2. BDA-366 Induces Bcl2 Conforma-
tional Change via Exposure of Its BH3
Domain, Leading to Conversion of Bcl2
from a Survival into a Killer Molecule
(A) Purified recombinant Bcl2 was treated with
increasing concentrations of BDA-366 in 1% (3-
[(3-cholamidopropyl)dimethylammonio]propane-
sulfonate) (CHAPS) lysis buffer, followed by IP
using anti-Bcl2/BH3 domain antibody. BH3
domain-exposed Bcl2 was analyzed by western
blot using Bcl2 antibody.
(B and C) H460 cells were treated with BDA-366
for 24 hr, followed by immunostaining using anti-
Bcl2/BH3 domain antibody (B) or MitoSOX red
staining (C). The scale bar represents 5 mm.
(D and E) H460 cells were treated with increasing
concentrations of BDA-366. Cyt c release (D)and
PARP cleavage (E) were analyzed.
(F) Purified Bcl2 in the absence or presence of Bax
protein was treated with BDA-366 or BAM7, fol-
lowed by IP using 6A7 Bax antibody. Conforma-
tionally changed Bax (i.e., active form of Bax) was
analyzed by western blot using Bax antibody.
(G) H460 cells were treated with increasing con-
centrations of BDA-366. A co-IP was performed
using agarose-conjugated Bcl2 antibody. Bcl2-
associated Bax or Bim was analyzed by western
blot.
See also Figure S2.2006, 2009; Lin et al., 2004). To test whether BDA-366 directly in-
ducesBcl2 conformational change, an in vitro cell-free assaywas
employed. Purified recombinant Bcl2 protein was incubatedwith
increasing concentrations of BDA-366 in lysis buffer, followed by
immunoprecipitation (IP) using the anti-Bcl2/BH3 domain anti-
body. Results indicate that addition of BDA-366 enhanced the
ability of the Bcl2/BH3 domain-specific antibody to bind Bcl2,
and this occurred in a dose-dependent manner (Figure 2A).
These findings appear to provide direct evidence for the notion
that binding of BDA-366 with the BH4 domain is able to alter
Bcl2’s conformation, leading to greater exposure of its own
BH3 domain. Since only BDA-366, but not a chemotherapeutic
agent (i.e., VP-16or cisplatin), candirectly induceBcl2 conforma-
tional change in a cell-free system (Figure S2A), this shows spec-
ificity for BDA-366 induction of such conformational change.
BDA-366-induced Bcl2 conformational change was also
confirmed by immunofluorescence using a Bcl2/BH3 domain-
specific antibody as previously described (Deng et al., 2006,
2009; Lin et al., 2004). Bcl2 immunofluorescence was low or un-Cancer Cell 27, 852–detectable in untreated H460 cells, and
it was enhanced significantly in cells
treated with BDA-366 (Figure 2B). How-
ever, treatment of H460 cells with BDA-
366 did not significantly affect Bcl2
expression level (Figure S2B). These
findings suggest that the negative regula-
tion of Bcl2 activity by BDA-366 occurs
through conformational change, and not
by a change in its expression.
Because treatment of H460 cells
with BDA-366 resulted in mitochondrialdysfunction (i.e., reduced MitoSOX red staining and cytochrome
c [Cyt c] release) and apoptosis [i.e., poly(ADP-ribose) polymer-
ase PARP cleavage] (Figures 2C–2E), the binding of BDA-366 to
the BH4 domain may cause exposure of the Bcl2 BH3 domain,
which in turn renders Bcl2 eventually able to activate Bax, lead-
ing to apoptosis. To test this possibility, a 6A7 Bax antibody that
only recognizes the conformationally changed, active form of
Bax was employed (Hsu et al., 1997; Hsu and Youle, 1998). First,
purifiedBcl2was treatedwith BDA-366 in lysis buffer for 1 hr. The
mixture of Bcl2/BDA-366 was then incubated with purified re-
combinant Bax for another 2 hr, followed by IP using 6A7 anti-
body. Results indicate that BDA-366-treated Bcl2, but not Bcl2
alone, enhanced the ability of Bax to bind to 6A7 antibody (Fig-
ure 2F, lane 4 versus lanes 5–7), indicating that BDA-366-treated
Bcl2 can induce Bax conformational change, leading to Bax acti-
vation. BAM7 is a recently identified Bax activator that can
directly activate Bax by binding to a Bax trigger site (Gavathiotis
et al., 2012). Importantly, BAM7, but not BDA-366, can directly
activate Bax (Figure 2F, lane 2 versus lane 3). These findings863, June 8, 2015 ª2015 Elsevier Inc. 855
Figure 3. BH3 Domain in Bcl2 Is Essential
for BDA-366 Regulation of Bcl2 and Bax
Function and Cyt c Release
(A) 10 ng of purified WT and BH3 deletion mutant
(DBH3) Bcl2 protein was analyzed bywestern blot.
(B) Purified WT or DBH3 mutant Bcl2 in the
absence or presence of Bax protein was treated
with BDA-366 or BAM7, followed by IP using 6A7
Bax antibody. Conformationally changed Bax was
analyzed by western blot using Bax antibody.
(C) WT and BH3 deletion mutant (DBH3) Bcl2 were
stably expressed in H1299 cells.
(D) H1299 cells expressing WT, DBH3, or vector-
only control were treated with BDA-366 for 24 hr,
followed by co-IP using Bcl2 BH3-specific or 6A7
antibody, respectively.
(E) Isolated mitochondria from H1299 cells ex-
pressing WT, DBH3, or vector-only control were
treated with BDA-366 in mitochondrial buffer for
30 min at 30C. After centrifugation, Cyt c in su-
pernatant or mitochondrial pellet was analyzed by
western blot.
See also Figure S3.indicate that BDA-366 is not a direct Bax activator but that it can
induce Bcl2-dependent Bax activation (Figure 2F, lane 3 versus
lanes 5–7). To test whether BDA-366-induced Bcl2 conforma-
tional change increases interaction between Bcl2 and Bax in
cells, co-IP experiments were performed following treatment
of H460 cells with BDA-366. Results reveal that BDA-366
enhanced theBcl2/Bax interaction in associationwith decreased
Bcl2/Bim binding (Figure 2G), suggesting that the BH3-exposed
Bcl2 induced by BDA-366 may have greater ability to interact
with Bax than Bim, leading to activation of Bax’s cell killing func-
tion via a 6A7 conformational change in cancer cells.
To further test whether the BH3 domain of Bcl2 is essential for
BDA-366 activation of Bax, purified recombinant WT and the
BH3 deletion (DBH3) mutant Bcl2 proteins (Figure 3A) were incu-
bated with purified Bax protein in the absence or presence of
BDA-366, followed by IP with 6A7 antibody. Results indicate
that, in the presence of BDA-366, WT, but not the DBH3 mutant
Bcl2, can activate Bax via 6A7 conformational change in a cell-
free system (Figure 3B). To test this at the cellular or mitochon-
drial level, WT, DBH3 Bcl2 mutant, and empty vector (pCIneo)
were transfected into H1299 cells that express undetectable
levels of endogenous Bcl2 but high levels of endogenous Bax
(Figure 3C). Cells or isolated mitochondria from these cells
were treated with BDA-366, followed by IP with Bcl2 BH3 or
6A7 antibody, respectively. Results indicate that BDA-366
induced Bcl2 conformational change in association with Bax
activation in cells or isolated mitochondria containing WT Bcl2,
but not in cells or isolated mitochondria expressing DBH3 Bcl2
mutant or vector-only control (Figures 3D and S3A). These re-856 Cancer Cell 27, 852–863, June 8, 2015 ª2015 Elsevier Inc.sults suggest that exposure of Bcl2 BH3
domain induced by BDA-366 is required
for BDA-366 activation of Bax in cells or
isolated mitochondria. To further test
whether BDA-366 induces Cyt c release
from mitochondria in a Bcl2-dependent
manner, mitochondria were isolatedfrom H1299 cells expressing WT, DBH3 mutant Bcl2, or vec-
tor-only control. The isolated mitochondria were treated with
BDA-366 (1 mM) for 30 min at 30C. After centrifugation, Cyt c
in the supernatant (i.e., Cyt c release) was analyzed by western
blot. Results reveal that BDA-366 induced Cyt c release from
the mitochondria isolated from WT Bcl2, but not from DBH3
and vector-only control cells (Figure 3E). This indicates that
BDA-366-induced Cyt c release occurs in a Bcl2-dependent
manner, which also requires the BH3 domain in Bcl2.
BDA-366 Induces Apoptotic Cell Death in a Bax-
Dependent Manner
Our findings mentioned above reveal that the BDA-366-induced
conformationally changed Bcl2 (i.e., with exposed BH3 domain)
can activate Bax (Figures 2 and 3). To further determine whether
Bax isessential forBDA-366 inductionof apoptosis,we tested the
apoptotic effect of BDA-366 on WT and Bax knockout (Bax/)
mouse embryonic fibroblast (MEF) cells. Intriguingly, Bax-defi-
cientMEFcellswere significantly resistant toBDA-366compared
toWTMEF cells (Figures S3B and S3C), indicating that activation
of Bax by conformationally changed Bcl2 may be an essential
step for the eventual induction of apoptosis by BDA-366.
BDA-366 Induces Ca2+ Release via Inhibition of Bcl2/
IP3R Interaction
Bcl2 has been reported to inhibit Ca2+-driven apoptosis by direct
interaction with the inositol 1,4,5-trisphosphate receptor (IP3R)
via the BH4 domain (Monaco et al., 2012; Rong et al., 2009).
Disruption of BH4/IP3R association by synthetic BH4 binding
Figure 4. BDA-366 Potently Represses Lung Cancer In Vivo
(A) Nu/Nu nude mice were treated with increasing doses (10–50 mg/kg/day) of
BDA-366 i.p. for 12 days (n = 6 mice per group). The percentage survival of
mice was calculated.
(B) Nu/Nu nude mice with H460 lung cancer xenografts were treated with
increasing doses of BDA-366 (0, 10, 20, and 30 mg/kg/day) for 14 days (n = 6
mice per group). Tumor volume was measured once every 2 days. After
14 days, themicewere sacrificed, and the tumorswere removed and analyzed.
All p values are compared with control group. Error bars represent ± SD.
(C) Active caspase-3 by IHC staining or TUNEL assay was performed in tumor
tissues at the end of experiments and quantified as described in Supplemental
Experimental Procedures. The scale bar represents 10 mm.
See also Figure S4.peptide resulted in increased Ca2+ release and apoptosis (Rong
et al., 2008; Zhong et al., 2011). To test whether BDA-366/BH4
binding affects the Bcl2/IP3R interaction and Ca2+ release,
H460 cells were treated with increasing concentrations of
BDA-366 for 24 hr. Results reveal that BDA-366 reduced Bcl2/
IP3R binding in association with increased Ca2+ release (Figures
S3D and S3E). These findings may uncover an additional mech-
anism by which BDA-366 induces apoptosis in a BH4 binding-
dependent manner.
BDA-366 Induces Autophagic Cell Death of Human Lung
Cancer Cells
It is well known that Bcl2 directly interacts with Beclin-1 and sup-
presses Beclin-1-dependent autophagy (Pattingre et al., 2005).Inhibition of Bcl2 by ABT-737 not only induces apoptosis but
also autophagy (Maiuri et al., 2007). Importantly, a recent report
indicates that removal of the BH4 domain from Bcl2 protein
promotes an autophagic process that impairs tumor growth
(Trisciuoglio et al., 2013). To test whether disruption of Bcl2
BH4 by BDA-366 stimulates autophagy, H460 cells were treated
with BDA-366 (1 mM) for 24 hr. Increased levels of microtubule-
associated protein-light chain 3-II (LC3-II) were observed after
treatment with BDA-366 (Figure S3F). To further quantify the
level of autophagy, a GFP-LC3 construct was used to indicate
autophagosomes as previously described (Liang et al., 2006;
Maiuri et al., 2007). After treatment with BDA-366, GFP-LC3 re-
distributes from a diffuse staining pattern in the cytoplasm and
nucleus to a cytoplasmic punctate structure that specifically
labels pre-autophagosomal and autophagosomal membranes
(i.e., GFP-LC3 vac cells) (Figure S3G). Treatment of cells with
BDA-366 significantly increases the percentage of GFP-LC3vac
cells compared to DMSO control (Figure S3H). These findings
reveal that, in addition to apoptosis, BDA-366may also stimulate
autophagic cell death by inhibiting Bcl2 activity in human lung
cancer cells.
BDA-366 Suppresses Lung Cancer Growth via Induction
of Apoptosis in Animal Models
In order to define the appropriate doses for in vivo experimenta-
tion, we first determined the maximum tolerated dose (MTD) as
previously described (Park et al., 2013). Nu/Nu nude mice were
treated in groups of six per dose level with increasing doses of
BDA-366 (10–50 mg/kg/day) intraperitoneally (i.p.) for up to
12 days. Doses of 40 and 50 mg/kg/day were uniformly lethal
in the six mice within 8 or 12 days, respectively (Figure 4A).
The dose range between 10 and 30 mg/kg/day was tolerable,
with no death recorded for up to 12 days of daily administration
(Figure 4A). To uncover the mechanism of lethality, in addition to
12-day treatment at the MTD as shown in Figure 4A, we also
measured standard single-dose MTD treatment in normal
C57BL/6 mice as previously described (Hamblett et al., 2004).
Treatment of mice with a single dose of 300 mg/kg i.p. did not
cause weight loss or other toxicities, including hematologic dis-
orders, or liver and kidney function abnormalities (Figures S4A–
S4C). However, a single dose of 400 mg/kg resulted in death
of mice in 4 days. Both alanine transaminase (ALT) and aspartate
transaminase (AST) were significantly elevated (Figures S4A
and S4B). Pathological analysis for all organs indicated micro-
steatosis in the liver and atrophic white pulp in the spleen (Fig-
ure S4C). Based on these findings, mice might die mainly from
liver damage at a single 400-mg/kg dose. Thus, the single-
dose MTD of BDA-366 should range from 300 to 400 mg/kg.
10% of single-dose MTD can usually be considered as the
maximum therapeutic dose (30–40 mg/kg) for continuous
treatment. We therefore considered doses between 10 and
30 mg/kg/day to be relatively safe.
To test the potency of BDA-366 in vivo, lung cancer xenografts
derived from H460 cells were treated with increasing doses (0,
10, 20, and 30 mg/kg/day) of BDA-366 via i.p. route for
14 days. Results show that treatment of mice with BDA-366
resulted in a dose-dependent repression of lung cancer in vivo
(Figure 4B). To assess whether BDA-366 induced suppression
of tumor growth via apoptosis in vivo, representative samplesCancer Cell 27, 852–863, June 8, 2015 ª2015 Elsevier Inc. 857
Figure 5. BDA-366 Represses Tumor Growth in Xenografts Derived
from SCLC Patient
Mice carrying xenografts derived from a patient with refractory SCLC were
treated with BDA-366 (20 mg/kg/day) i.p. for 2 weeks (n = 6 mice per group).
(A and B) Tumor volume (A) and active caspase-3 in tumor tissues (B) were
analyzed. Error bars represent ± SD. The scale bar represents 10 mm.from harvested tumor tissues were analyzed by immunohisto-
chemistry (IHC) for active caspase-3 or terminal deoxynucleo-
tidyl transferase dUTP nick-end labeling (TUNEL) assay as
previously described (Hao et al., 2012; Oltersdorf et al., 2005).
A dose-dependent apoptosis induction was observed in tumor
tissues after BDA-366 treatment (Figure 4C). Importantly, doses
of 10–30 mg/kg/day not only potently suppressed tumor growth
but also were well tolerated without significant toxicity to mice.
Slight weight loss was observed in mice treated with the dose
of 30 mg/kg, but there were no decreases in neutrophils, lym-
phocytes, red blood cells (RBCs), and platelets (PLTs) in blood.
Tests of kidney (blood urea nitrogen [BUN]) and liver (ALT and
AST) function were in the normal range (Figures S4D and S4E).
Histopathology of harvested normal tissues (heart, liver, lung,
brain, spleen, kidney, intestine, etc.) revealed no evidence of
normal tissue toxicities after treatment with doses of 10–
30 mg/kg/day (Figure S4F). These findings suggest that doses
between 10 and 30 mg/kg provide the optimal therapeutic index
for BDA-366 for in vivo experimentation involving lung cancer
xenografts.
In addition to NSCLC cell lines, BDA-366 also efficiently
suppressed growth of SCLC cell lines (Figure 1). To evaluate
the antitumor activity of BDA-366 against SCLC in vivo, we
established patient-derived xenografts (PDXs), without inter-
vening in vitro culture, which are expected to better recapitulate858 Cancer Cell 27, 852–863, June 8, 2015 ª2015 Elsevier Inc.the human SCLC tumor setting. We tested the potency of BDA-
366 (20 mg/kg/day) administered for 2 weeks in a PDX obtained
from a patient with refractory SCLC. Intriguingly, BDA-366
potently suppressed the growth of the SCLC PDX, which
occurred through apoptosis in tumor tissues (Figure 5). These
findings indicate that BDA-366 may potentially be effective in
patients with SCLC where there are currently limited treatment
options.
BDA-366 InducesBcl2 Conformational Change in Tumor
Tissues
Quantum dot-based immunohistofluorescence (QD-IHF) tech-
nology has recently been developed as a valuable tool for
simultaneous and concurrent immunostaining of multiple bio-
markers in formalin-fixed paraffin-embedded (FFPE) tissues,
thereby allowing for quantification of several biomarkers simul-
taneously on the same tissue slide (Li et al., 2013). To deter-
mine whether BDA-366 induces Bcl2 conformation change by
exposure of its BH3 domain in tumor tissues and whether
the BH3 domain-exposed Bcl2 activates Bax, conformational
changes in both Bcl2 and Bax were simultaneously analyzed
by QD-IHF on the same tissue slide. The antibody 6A7 can
selectively recognize Bax after the conformational change
associated with membrane insertion that occurs in apoptotic
cells (Hsu et al., 1997; Hsu and Youle, 1998). QD images
showed that treatment of H460 xenograft mice with BDA-366
for 14 days resulted in a dose-dependent exposure of the
Bcl2 BH3 domain in tumor tissues (Figure 6). Intriguingly,
BDA-366-induced Bcl2 conformational change was associated
with an increased level of 6A7 binding to Bax (i.e., an increase
in the level of the active form of Bax; Figure 6), suggesting that
the BH3-exposed Bcl2 may activate Bax, leading to apoptosis
in tumor tissues (Figure 4C). There were no significant changes
in total Bcl2 and Bax levels in tumor tissues after BDA-366
treatment (Figure S5).
mTOR Inhibition Upregulates Bcl2 in Lung Cancer Cell
Lines and in Tumor Tissues from Patients with NSCLC
Rapamycin and its derivative, RAD001 (i.e., everolimus), are
potent allosteric inhibitors of mammalian target of rapamycin
(mTOR) (Legrier et al., 2007). RAD001 is well tolerated, but it
shows limited antitumor activity in patients with lung cancer
(Besse et al., 2014; Ramalingam et al., 2013; Tarhini et al.,
2010). Previous reports indicate that expression of Bcl2 is asso-
ciated with resistance of cancer cells to mTOR inhibitors (Aguirre
et al., 2004; Majumder et al., 2004). To further test whether
mTOR inhibition regulates Bcl2 expression, A549 and H460 cells
were treated with increasing concentrations of RAD001 for 24 hr.
Inhibition of mTOR by RAD001 resulted in upregulation of Bcl2 in
a dose-dependent manner in both A549 and H460 lung cancer
cells (Figure 7A). To test whether a similar effect of RAD001 on
Bcl2 expression occurs in patients, we analyzed Bcl2 expression
by IHC in baseline and post-treatment tissue samples obtained
from ten NSCLC patients treated with RAD001 (5 or 10 mg/day)
for 28 days as part of a neoadjuvant clinical study of everolimus
in patients with resectable NSCLC (Owonikoko et al., 2015).
There was increased expression of Bcl2 in post-treatment tumor
tissues compared to baseline samples (Figure 7B). These find-
ings suggest that upregulation of Bcl2 by mTOR inhibition may
Figure 6. BDA-366 Induces BH3 Domain
Exposure in Bcl2 in Association with Bax
Activation in Tumor Tissues
H460 lung cancer xenografts were treated with
increasing doses of BDA-366 for 14 days (n = 6
mice per group, three sections per animal). Bcl2
and Bax conformation changes were analyzed in
tumor tissues at the end of experiments by QD-
IHF using anti-Bcl2/BH3 domain antibody or anti-
6A7 Bax antibody, respectively, and quantified as
described in Supplemental Experimental Pro-
cedures. The scale bar represents 10 mm. Error
bars represent ± SD.
See also Figure S5.negatively affect the sensitivity of lung cancer to mTOR inhibitor.
Thus, inhibition of Bcl2may enhance the potency of mTOR inhib-
itor against lung cancer.
BDA-366 Synergizes with mTOR Inhibitor in
Suppression of Lung Cancer In Vitro and In Vivo
To test whether combined Bcl2 and mTOR inhibition shows the
predicted synergistic activity against lung cancer cells, H460
cells were treated with BDA-366 (100 nM), RAD001 (1 nM), or
the combination. SRB assay showed that either RAD001 or
BDA-366 alone partially inhibited lung cancer cell growth.
Intriguingly, the combination of RAD001 and BDA-366 resulted
in significantly greater growth inhibition (Figure S6A), indicating
that combined Bcl2 and mTOR inhibition has greater activity
than either single agent alone in inhibiting lung cancer cell
growth. To more accurately analyze the degree of synergy be-
tween RAD001 and BDA-366, a combination index (CI) value
was calculated as described in Supplemental Experimental Pro-
cedures. The CI value was less than 0.3 (i.e., 0.278), indicatingCancer Cell 27, 852–that RAD001 and BDA-366 exhibit strong
synergistic growth inhibition of lung can-
cer cells.
To test whether co-targeting Bcl2
and mTOR also synergistically represses
lung cancer in vivo, mice with NSCLC
(i.e., H460) xenografts were treated
with RAD001 (1 mg/kg/day), BDA-366
(15 mg/kg/day), or the combination for
14 days. Intriguingly, the combination
of BDA-366 and RAD001 exhibited a
significantly greater efficacy than BDA-
366 or RAD001 alone in suppressing
lung tumor growth in vivo (Figure 8A),
leading to sustained tumor repression.
One of the six tumor-bearing mice
treated with combined BDA-366 and
RAD001 achieved complete tumor
regression, which is still persisting as of
the time of euthanization (4 months
from the end of treatment on day 14).
Importantly, RAD001 alone did not
cause significant apoptosis in tumor tis-
sues, but it significantly enhanced the
apoptosis induced by BDA-366 in tumortissues (Figure 8B). No weight loss or organ toxicities were
observed in mice with these treatments, including combined
treatment (Figures 8C, 8D, and S6B).
DISCUSSION
Bcl2 is a major antiapoptotic Bcl2 family member that is directly
involved in the suppression of apoptosis at the decision stage
(Deng et al., 2006). Mimicking the BH3 domain to induce
apoptosis has recently been used as a strategy for the develop-
ment of Bcl2 inhibitors as anticancer drugs (Chonghaile and
Letai, 2008; Kang and Reynolds, 2009; Oltersdorf et al., 2005).
The BH3 mimetic agents function as competitive inhibitors by
binding to the hydrophobic cleft of Bcl2/Bcl-XL (Chonghaile
and Letai, 2008; Oltersdorf et al., 2005). Four Bcl2 inhibitors, ob-
limersen sodium (G3139), gossypol (AT-101), obatoclax (GX15-
070), and ABT-263, have already been tested in human clinical
trials but showed limited clinical efficacy (Chonghaile and Letai,
2008; Kang and Reynolds, 2009).863, June 8, 2015 ª2015 Elsevier Inc. 859
Figure 7. Treatment of LungCancer Cells or
Patients with RAD001 Upregulates Bcl2
(A) A549 or H460 cells were treated with increasing
concentrations of RAD001 for 24 hr. Bcl2 and
p-p70S6K were analyzed by western blot.
(B) 10 patients with NSCLC were treated with
RAD001 (5 mg or 10 mg/day) for 28 days. Bcl2 in
tumor tissues was analyzed by IHC using anti-Bcl2
antibody and quantified by analyzing immuno-
score. The scale bar represents 10 mm. Error bars
represent ± SD.The BH4 domain is required for the survival activity of Bcl2,
and removal of this domain can convert Bcl2 from a survival to
a killer molecule (Cheng et al., 1997), suggesting that the BH4
domain constitutes a promising structure-based target for the
disruption of Bcl2’s survival function or conversion of Bcl2 into
a death molecule. In this study, we have identified a class of
Bcl2 antagonist (i.e., BDA-366) that targets the BH4 domain
and is distinct from previous BH3 mimetics. BDA-366 directly
binds to purified Bcl2 protein selectively at the BH4 domain
with high affinity, with an inhibitor constant (Ki) value at the nano-
molar level. BDA-366 failed to bind other Bcl2 family members
(i.e., Bcl-XL, Mcl-1, and Bfl-1/A1), demonstrating the specificity
of Bcl2/BDA-366 binding. The binding of BDA-366 with the
BH4 domain resulted in Bcl2 conformational change and expo-
sure of the BH3 domain in vitro and in vivo. This conformational
change could activate Bax in a cell-free system and also in tumor
tissues, suggesting that it is likely responsible for the death-
inducing effect of BDA-336. These findings suggest a mecha-
nistic model of using a small-molecule inhibitor to convert an
antiapoptotic Bcl2 family member(s) into a death molecule.
The multi-domain proapoptotic Bax provides the required
gateway to apoptotic cell death (Wei et al., 2001). Since BDA-
366 is dependent on Bax for apoptosis induction, this suggests
its mechanism of action may be predominantly through the Bcl2
family.However,direct activationofBaxappearsunlikelybecause
BDA-366 failed to induce Bax conformational change in vitro.
BDA-366 demonstrated potent antitumor activity in lung can-
cer xenografts derived from either a lung cancer cell line or a pa-
tient-derived SCLC tumor. We determined the MTD of BDA-366
with a 12-day treatment to be between 30 and 40 mg/kg/day.
Dose-response experiments revealed that doses of BDA-366
between 10 and 30 mg/kg/day potently suppress lung cancer860 Cancer Cell 27, 852–863, June 8, 2015 ª2015 Elsevier Inc.growth in vivo without platelet reduction
or other significant normal tissue toxicity,
indicating that this dose range should be
effective and safe in murine lung cancer
models. Since BDA-366 effectively sup-
pressed the growth of PDX raised from
a patient with refractory SCLC, there is a
good possibility that BDA-366 may pro-
vide clinical utility in patients in the future.
Cancer cells overexpressing Bcl2 are
resistant to mTOR inhibitor and downre-
gulation of Bcl2 restores sensitivity to
mTOR inhibition (Aguirre et al., 2004; Ma-
jumder et al., 2004). Here, we discoveredthat inhibition of mTOR by RAD001 resulted in Bcl2 upregulation
in lung cancer cell lines and in tumor tissues from NSCLC pa-
tients treated with RAD001. It is possible that Bcl2 expression
induced by mTOR inhibitor therapy may negatively affect the
efficacy of mTOR inhibitor in lung therapy. This may help explain
why RAD001 only had limited efficacy in lung cancer patients
(Ramalingam et al., 2013; Tarhini et al., 2010). Our findings pro-
vide a strong rationale to propose that combined Bcl2 andmTOR
inhibition should have superior therapeutic benefits over each
agent alone. As expected, BDA-366 in combination with
RAD001 exhibited strong synergistic activity against lung cancer
in vitro and in vivo without significant normal tissue toxicity.
Based on our data, we propose that co-targeting Bcl2 and
mTOR offers a more effective strategy for lung cancer treatment.
In summary, we have identified a class of Bcl2 antagonist
(BDA-366) that selectively targets the BH4 domain of Bcl2. The
binding of BDA-366 with the BH4 domain results in conversion
of Bcl2 from an antiapoptotic molecule into a death protein
through a conformational change that exposes its BH3 death
domain. The BH4 antagonist BDA-366 exhibits potent efficacy
against human lung cancer in vivo without platelet reduction.
Development of the BH4 antagonist as a class of anticancer
agent offers additional strategy for lung cancer therapy.
EXPERIMENTAL PROCEDURES
Detailed experimental information and reagents used in this study is provided
in Supplemental Experimental Procedures.
Cell Lines and Cell Culture
Normal small airway epithelial cells (SAECs) and lung cancer cell lines were
purchased from ATCC. SAECs were cultured in small airway epithelial growth
media (SAGM BulletKit, ATCC). NSCLC cell lines (i.e., H157, H358, H460,
Figure 8. Combination of BDA-366 and
RAD001 Synergistically Represses Lung
Cancer In Vivo
Nu/Nu mice with H460 lung cancer xenografts
were treated with BDA-366, RAD001, or their
combination i.p. for 14 days (n = 6 mice per
group).
(A–D) Tumor volume (A), active caspase-3 in tu-
mor tissues (B), body weight (C), and blood (D)
were analyzed. The scale bar represents 10 mm.
Error bars represent ± SD.
See also Figure S6.HCC827, H292, H1299, H1975, and Calu-1) were maintained in RPMI 1640
medium with 5% fetal bovine serum (FBS) and 5% bovine serum (BS). A549
cells were cultured in F-12K medium with 10% fetal bovine serum. WT and
Bcl2 BH deletion mutants (i.e., DBH1, DBH2, DBH3, and DBH4) were created
and stably expressed in H1299 cells as we previously described (Hou et al.,
2007; Wang et al., 2008). SCLC cell lines DMS53, DMS114, DMS153, H128,
H146, and H69 were cultured in Weymouth’s medium supplemented with
5% FBS and 5% BS as previously described (Park et al., 2013). WT and Bax
knockout (Bax/) MEF cells were obtained from Dr. Douglas R. Green (St.
Jude Children’s Research Hospital) and maintained in DMEM with 10% fetal
bovine serum.
Human Patient Samples from Clinical Trial and Establishment of
Patient-Derived Xenografts
Informed consent was obtained from all human subjects, and use of human
samples for immunohistochemistry and patient-derived xenograft was
approved by the institutional review board (IRB) of Emory University. Paired
samples of NSCLC tissues were collected as part of a completed phase Ib clin-
ical trial evaluating the pharmacodynamic effects of RAD001 in adult patients
with resectable NSCLC. Enrolled eligible patients received RAD001 (5 or
10 mg) orally once daily for 28 days (Owonikoko et al., 2015). Pretreatment
biopsy samples and post-treatment surgical resection specimens were
analyzed for Bcl2 expression. Patient-derived xenograft was obtained as
part of an IRB-approved phase II co-clinical trial of arsenic trioxide in patientsCancer Cell 27, 852–with relapsed SCLC who have failed standard
platinum-based chemotherapy. Tumor samples
were obtained by image guided biopsy and were
directly implanted into Nu/Nu nude mice without
intervening propagation in plastic culture plates.
Direct serial propagation of growing tumor
occurred for up to five generations. The animal
propagation protocol was approved by the Emory
Institutional Animal Care and Use Committee
(IACUC) and the Emory Animal Ethics Committee.
Treatment of Lung Cancer Xenografts
Lung cancer xenografts were generated as previ-
ously described (Park et al., 2013). Six-week-old
male Nu/Nu nudemice were purchased from Har-
lan and housed under pathogen-free conditions
in microisolator cages. All animal treatments
were undertaken in accordance with protocols
approved by the IACUC at Emory University. 3 3
106 lung cancer H460 cells were injected into sub-
cutaneous tissue in the flank region of nude mice.
The tumors were allowed to grow to an average
volume of 250 mm3 prior to initiation of therapy
as previously described (Oltersdorf et al., 2005).
Mice with lung cancer xenografts were treated
with BDA-366, RAD001, or the combination i.p.
at the indicated dose. During treatment, tumor
volume (V) was measured by caliper measure-ments once every 2 days and calculated with the formula V = (L3W2)/2, where
L is length and W is width, as previously described (Park et al., 2013). At the
end of experiments, mice were euthanized by CO2 inhalation. Harvested tumor
tissues were used for further analysis.
Statistical Analysis
The statistical significance of differences between groups was analyzed with
two-sided unpaired Student’s t test or Fisher’s exact test. Results were
considered statistically significant at p < 0.05. The half maximal inhibitory con-
centration (IC50) values were calculated using SPSS Statistics software 18
(IBM). All data are presented as mean ± SD.
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